LTP.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	LTR Pharma Ltd (LTP.ASX)
Release Time	28 Jul 2026, 9:01 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

LTR Pharma Q2 2026 Update: Clinical Milestones and U.S. Launch Prep

Key Points

SPONTAN Phase II interim data shows rapid absorption with no accumulation
U.S. commercial agreements for ROXUS secured with Shed and Strive
Strong financial position with A$19.6 million cash as at June 2026
OROFLOW study approval for Oesophageal Motility Disorders

Full Summary

LTR Pharma Limited (ASX: LTP) has released its Quarterly Activities Report and Appendix 4C for the three months ended 30 June 2026. The company has made substantial progress in its clinical and commercial initiatives. Interim data from the SPONTAN Phase II study demonstrated a median Tmax of 10 minutes, significantly faster than oral vardenafil. Additionally, the company secured definitive commercial agreements with Shed and Strive for the U.S. launch of ROXUS. LTR Pharma also received ethics approval for an OROFLOW study in Oesophageal Motility Disorders, expanding its intranasal platform. The company maintained a strong financial position with A$19.6 million in cash and zero debt as at 30 June 2026.

Outlook

LTR Pharma is preparing for the U.S. commercial launch of ROXUS and advancing SPONTAN toward FDA submission, with a focus on disciplined capital allocation.